Mazdutide

Synonyms: BI 456906, GLP-1/Glucagon receptor agonist, 2259884-03-0

Mazdutide is a synthetic peptide dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Innovent Biologics in partnership with Eli Lilly, it is currently in clinical development for the treatment of type 2 diabetes and obesity. The peptide combines the glucose-lowering effects of GLP-1 with the energy-expending effects of glucagon, offering a promising approach to addressing metabolic disorders.

Product Highlights

• Dual agonist activity: Simultaneously activates GLP-1 and glucagon receptors for enhanced metabolic benefits.
• High purity: ≥98% as determined by HPLC, ensuring reliable and reproducible results.
• Research-grade quality: Manufactured under strict quality control, with comprehensive COA and MSDS provided.
• Custom packaging: Available in various sizes to meet different research needs.
• Technical support: Our team of experts is available to assist with any questions regarding handling or storage.

Applicazioni

• Metabolic disease research, including type 2 diabetes and obesity.
• Studies on GLP-1 and glucagon receptor signaling pathways.
• Development of novel therapeutic peptides for metabolic disorders.

Caratteristiche tecniche

Ordering & Supply

• Imballaggio: 5 g, 10 g, 50 g, 100 g, or customized
• MOQ: 5 g
• Tempi di consegna: 1-2 weeks after order confirmation
• Documentazione: COA, MSDS, TDS provided

Richiesta di preventivo

• Il nostro indirizzo: 280 Main Street, Xian, Shaanxi, Cina
• LyvBio S.r.l. — E-mail: info@lyvbio.com